Bio-Reference Laboratories, Inc. (NASDAQ:BRLI)

marketmomentum (< 20) Submitted: 8/10/2009 6:47:17 PM : Start Price: $14.93 BRLI Score: -4.54

No need for them after H1N1 gets you.

YONOSENADA (< 20) Submitted: 7/12/2009 2:02:53 PM : Start Price: $15.02 BRLI Score: -14.62

Company has found a nice recipe to keep doing a business despite the current 2009 economy.
CEO, which is a Founder, still wants to grow the company.
Fundamentals looks almost spot less. Cash in not one of the strongest... Dr. Grodman may be like may bro: Cannot keep money in his pockets; however may bro uses it not as wise as Dr G.

dragofly (< 20) Submitted: 11/28/2008 5:36:24 PM : Start Price: $10.88 BRLI Score: +32.44

Good financials, strong balance sheet. Low in debt. starting to beat the S&P and with room to grow.

thestinkyfeet (98.48) Submitted: 8/2/2008 12:58:51 PM : Start Price: $12.16 BRLI Score: +56.87

The reasoning behind the selection of this stock, and a board on which to discuss the stock, or whatever else you like, can be found on the MF Stinky Feet discussion board at http://boards.fool.com/Messages.asp?mid=26829411&bid=119057&days=7 . Hope to see you there.

waterford9 (57.48) Submitted: 4/24/2008 9:31:55 PM : Start Price: $12.21 BRLI Score: +68.67

got a feeling

drbabyblueeyes (< 20) Submitted: 4/29/2007 10:34:44 AM : Start Price: $13.44 BRLI Score: +58.25

Baby boomers, that's all I have to say.

NetscribeHealthC (23.30) Submitted: 1/31/2007 7:16:01 AM : Start Price: $11.39 BRLI Score: +80.62

Bio-Reference is a leading independent regional clinical laboratory in five northeastern states in the U.S., processing over 3 million lab test requisitions every year. The company’s routine and esoteric laboratory testing services have major market positions in physician offices, nursing homes and correctional institutions. The company operates GenPath, a cancer and oncology laboratory, which is one of the premier hematopathology laboratories in the U.S. The company also operates a clinical knowledge management service, which uses customer data to provide clinical decision support systems.

The company faces competition from large clinical laboratories, LabCorp and Quest, and numerous hospital-based laboratories. To keep up with the competition, the company acquired GeneDx in 2006, a leading DNA sequencing laboratory. As molecular testing in general becomes a more significant element in the diagnostic testing industry, DNA testing will become an essential diagnostic tool in the future.

The U.S. health expenditures are expected to rise by 7.1% annually to $3 trillion by 2010. Given the ageing demographic trends in the U.S., the healthcare services business is expected to grow over 5% per annum till 2010. The number of specialty clinics and laboratories is expected to rise by 3%, the fastest among all medical facilities, boosted by esoteric testing facilities. Bio-Reference is catching pace quickly in terms of infrastructure and services offered.

Revenues for the quarter ended October 2006 were 22% higher, reflecting a 6% increase in patients serviced primarily. Also, revenue per patient saw a rise of 17% due to a shift in business to higher reimbursement esoteric testing, which grew by 41%. The company's esoteric testing business remains strong, and it is expected that cancer and genetic testing will drive continued growth over the next two years. Additionally, expansion of the GenPath operations and the acquisition of GeneDx would affirmatively boost revenues by more than 20% making the company a likely outperformer.

hybridinvestor (26.29) Submitted: 12/19/2006 3:12:35 PM : Start Price: $11.73 BRLI Score: +74.97

Was waiting for this one to start pulling back. Great little lab testing company which is not cheap per various multiples but well run and I think very strongly a takeout play with either LH or DGX being the suitor. I owned and sold off recently at $24.50ish and was hoping for a pullback to start averaging back into this one.

5STARsmallCAPS (78.14) Submitted: 11/11/2006 2:23:14 PM : Start Price: $12.10 BRLI Score: +66.96

5-star $314 million market cap on 11/11/06
NYC area medical labs.
5STARsmallCAPS picks five star stocks with the smallest market caps.

boyet7 (85.75) Submitted: 10/5/2006 2:24:03 PM : Start Price: $10.90 BRLI Score: +81.61

earning per share rating of 94
relative strength rating of 89
within 5% of 52 week high

tjminner (97.91) Submitted: 9/30/2006 7:16:39 AM : Start Price: $11.19 BRLI Score: +77.11

RIGHT SECTOR RIGHT TIME

Whoop04 (92.77) Submitted: 9/28/2006 10:03:14 PM : Start Price: $11.47 BRLI Score: +72.86

9/2006

Earnings Per Share (EPS) Rating
94
Relative Price Strength (RS) Rating
89
Industry Group Relative Strength (Grp RS) Rating
B+
Sales + Profit Margins + ROE (SMR) Rating
B
Accumulation/ Distribution (Acc/Dis) Rating
B+

Ozzymandiaz (< 20) Submitted: 9/19/2006 9:05:31 PM : Start Price: $12.11 BRLI Score: +62.20

technically it seems like it will break out of resistance soon.

ac11166 (< 20) Submitted: 8/29/2006 4:26:48 PM : Start Price: $10.56 BRLI Score: -84.81

May be trading at an acquisition premium today. Premium to peers is definitely not supported by historical growth rate or risks inherent in "price taker" position with Medicare and Medicaid.